Literature DB >> 15385421

A single-chain tetradomain glycoprotein hormone analog elicits multiple hormone activities in vivo.

Vicenta Garcia-Campayo1, Irving Boime, Xiaoping Ma, Dorit Daphna-Iken, T Rajendra Kumar.   

Abstract

We previously demonstrated that genetically linking one or more of the glycoprotein hormone-specific beta subunit genes to the common alpha subunit resulted in single-chain analogues that were bioactive in vitro. The ability of such large structures to bind their cognate receptors with high affinity supported the hypothesis that extensive flexibility exists between the ligand and receptor to establish a functional complex. To further characterize the extent of this conformational flexibility, we engineered a single-chain analogue that consists of sequentially linked thyroid-stimulating hormone (TSH) beta, follicle-stimulating hormone (FSH) beta, and chorionic gonadotropin (CG) beta subunits to the alpha subunit and expressed this chimera in transfected CHO (Chinese hamster ovary) cells. Because the four subunits are genetically linked and expressed as a single-chain, this analogue presumably lacks significant native structural features of the individual heterodimers. However, it exhibited FSH, CG, and TSH activities in vitro. Here, we test whether this nonnative structure would be stable in vivo and thus biologically active. Using a variety of bioassay protocols, we demonstrate that the analogue elicits multihormone activities when injected in vivo. First, treatment with the analogue caused increases in ovarian and uterine weights and resulted in elevated serum estradiol. Second, the analogue-stimulated ovarian follicle growth and pharmacologically rescued in vivo FSH deficiency similar to recombinant human FSH or equine CG (eCG) as confirmed by induction of aromatase in the ovaries of FSHbeta knockout mice. Third, in a superovulation protocol, when primed with eCG, the analogue elicited a dose-dependent ovulatory response comparable with that by native heterodimeric human CG. Finally, the analogue-stimulated thyroxin production in hypothyroid mice similar to the pituitary-derived human TSH standard. Based on these data, we conclude that a single-chain tetradomain glycoprotein hormone analogue, despite its presumed altered conformation, is stable and biologically active in vivo. Our results establish the permissiveness and conformational plasticity with which the glycoprotein hormones are recognized in vivo by their target cell receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385421     DOI: 10.1095/biolreprod.104.031732

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  6 in total

Review 1.  Fshb Knockout Mouse Model, Two Decades Later and Into the Future.

Authors:  T Rajendra Kumar
Journal:  Endocrinology       Date:  2018-05-01       Impact factor: 4.736

Review 2.  Minireview: Insights Into the Structural and Molecular Consequences of the TSH-β Mutation C105Vfs114X.

Authors:  Gunnar Kleinau; Laura Kalveram; Josef Köhrle; Mariusz Szkudlinski; Lutz Schomburg; Heike Biebermann; Annette Grüters-Kieslich
Journal:  Mol Endocrinol       Date:  2016-07-07

Review 3.  Gonadotropin gene targeting and biological implications.

Authors:  T Rajendra Kumar
Journal:  Endocrine       Date:  2005-04       Impact factor: 3.633

4.  Evaluation of in vivo bioactivities of recombinant hypo- (FSH21/18) and fully- (FSH24) glycosylated human FSH glycoforms in Fshb null mice.

Authors:  Huizhen Wang; Jacob May; Viktor Butnev; Bin Shuai; Jeffrey V May; George R Bousfield; T Rajendra Kumar
Journal:  Mol Cell Endocrinol       Date:  2016-08-22       Impact factor: 4.102

Review 5.  FSHbeta knockout mouse model: a decade ago and into the future.

Authors:  T Rajendra Kumar
Journal:  Endocrine       Date:  2009-04-23       Impact factor: 3.633

Review 6.  Novel insights on thyroid-stimulating hormone receptor signal transduction.

Authors:  Gunnar Kleinau; Susanne Neumann; Annette Grüters; Heiko Krude; Heike Biebermann
Journal:  Endocr Rev       Date:  2013-05-03       Impact factor: 19.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.